Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
58.97 USD | -0.66% | -8.44% | -28.42% |
May. 13 | Transcript : Cytokinetics, Incorporated - Special Call | |
May. 09 | Oppenheimer Adjusts Cytokinetics Price Target to $106 From $107, Maintains Outperform Rating | MT |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- Based on current prices, the company has particularly high valuation levels.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-28.42% | 6.22B | B | ||
+6.02% | 111B | B+ | ||
+12.24% | 106B | B+ | ||
-12.34% | 22.24B | B+ | ||
-1.16% | 21.25B | B | ||
-5.01% | 18.97B | A- | ||
-35.21% | 18.52B | A- | ||
-11.16% | 16.81B | B | ||
+38.95% | 12.54B | C+ | ||
-25.40% | 8.09B | D |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- CYTK Stock
- Ratings Cytokinetics, Incorporated